An association between EGFR activity and an immune cold phenotype has been previously reported in multiple cancers, including HNSCC [50,66,98,99], and clinical trials reported lower benefit from ICI therapy for non-small cell lung cancer with EGFR mutations [100,101]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.